SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report February 22, 1995
BARR LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
New York 1-9860 22-1927534
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519
(Address of principal executive offices) (Zip code)
(914) 362-1100
(Registrant's telephone number, including area code)
<PAGE>
BARR LABORATORIES, INC.
CURRENT REPORT dated February 22, 1995
Item 5. Other Events
On February 17, 1995, the Registrant completed the conversion
of the entire $10 million principal amount of all outstanding
10.05% Convertible Subordinated Notes to 510,358 common shares
of Barr Laboratories stock. The noteholders informed the
Registrant that the shares, received for the conversion, were
privately placed.
Item 7. Financial Statements, and Exhibits
(c) Exhibits
1. Registrant's February 13, 1995 press release
announcing that its noteholders had elected to convert the
entire $10 million principal amount of all outstanding 10.05%
Convertible Subordinated Notes to common shares of Barr
Laboratories stock.
<PAGE>
BARR LABORATORIES, INC.
CURRENT REPORT dated February 22, 1995
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
BARR LABORATORIES, INC.
Date: February 22, 1995 /S/ Paul M. Bisaro
Paul M. Bisaro
Vice President, Chief Financial
Officer,General Counsel and Corporate
Secretary
<PAGE>
BARR LABORATORIES, INC.
CURRENT REPORT dated February 22, 1995
EXHIBIT INDEX
The following exhibit is filed with this Report:
Exhibit No. Description
99 Registrant's press release dated February 13, 1995.
[ARTICLE] 5
Barr Laboratories, Inc.
2 Quaker Road, P.O. Box 2900
NEWS RELEASE
Pomona, NY 10970
914-362-1100
CONTACT: Charles M. Mayr, 914-348-8050
Barr Laboratories Announces Conversion of Debt to Common Stock
Pomona, New York, February 13, 1995.....Barr Laboratories,
Inc. (AMEX-BRL) today announced that its noteholders have
elected to convert the entire $10 million principal amount of
all outstanding 10.05% Convertible Subordinated Notes to
common shares of Barr Laboratories stock. The noteholders
will receive approximately 510,000 shares. Barr expects that
the transaction will be completed within ten days. The
noteholders have informed the Company that the shares,
received for the conversion, are expected to be privately
placed.
Although the Convertible Subordinated Notes were due June 28,
2001, Barr elected to prepay the debt so that the noteholders
had the option of taking common stock or a cash payment
equivalent to $10 million plus a make-whole amount of
approximately $750,000.
Barr Laboratories, Inc. is a leading independent developer,
manufacturer and marketer of high quality generic
pharmaceuticals. The Company manufactures and distributes a
wide range of generic prescription drug products in various
dosage forms and strengths. Barr's administrative offices and
research and development, manufacturing and distribution
facilities are located in Blauvelt and Pomona, New York, and
Northvale, New Jersey.
